<DOC>
	<DOC>NCT01237028</DOC>
	<brief_summary>This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.</brief_summary>
	<brief_title>Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Biopsyproven Ig AN patients aged 2070 years Patients with residual proteinuria &gt; 500 mg/g creatinine despite reninangiotensin system blockade and adequate blood pressure control for more than 3 months Patients who give informed consent, and 4) estimated GFR &gt;= 30 ml/min/1.73 m2. patients &lt; 20 years or &gt; 70 years hypersensitivity to vitamin D analogs patients who need urgent dialysis hypercalcemia within 3 months (uncorrected serum calcium level &gt; 10.2 mg/dL) clinical features of rapidly progressive glomerulonephritis life expectancy less than 24 months uncontrolled hypertension decompensated liver or lung disease symptomatic heart failure (NYHA class IIIV or LVEF &lt; 40%) estimated GFR &lt; 30 ml/min/1.73 m2.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>